Bellevue Group AG
•CIK: 1674546•Filing: Q4 2025
Bellevue Group AG, with $5.3 billion in assets under management, is currently focused on biotech and healthcare sectors, as evidenced by top holdings like Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX). The fund, known for its active management style, recently made notable moves by adding Gilead Sciences (GKOS) and Merck (MRK) significantly, while exiting positions in Allogene Therapeutics (AGIO) and Akero Therapeutics (AKRO).
Total AUM
$5.3B
QoQ Performance
+9.6%
Positions
176
Top 10 Concentration
49.5%
Latest Filing
Q4 2025
Top Holdings Allocation
RVMD
ARGX
ISI
VRTX
RVMD7.6%
ARGX7.4%
ISI7.2%
VRTX5.9%
NBIX4.6%
RNAGBP3.6%
ISRG3.5%
SRRK3.4%
📈 Biggest Buys
📉 Biggest Sells
Sector Breakdown
Other89.3%
Healthcare10.6%
Technology0.1%
ETF0.0%
Financial0.0%
Consumer0.0%
🚪 Exited Positionssold since Q3 2025
+4 more exited positions
Changes from Q3 2025
NEW37 new positions
↑47 increased
↓83 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023